OCONNOR, a UBS Asset Management unit, significantly reduced its stake in Packaging Corporation of America (PKG) by 94.3% in the fourth quarter, now holding 4,290 shares valued at approximately $885,000. Despite this reduction, Wall Street analysts maintain a "Moderate Buy" rating for PKG, with an average price target of $241.83. The company recently reported strong quarterly earnings of $2.40 per share, surpassing estimates, and increased its quarterly dividend to $1.50 per share, or $6.00 annually.

BrewDog USA, a unit of Tilray Brands (NASDAQ: TLRY), announced widespread summer soccer watch parties and fan events at its U.S. bars in Las Vegas and Ohio. These events capitalize on the 2026 global soccer tournament, offering drink specials, giveaways, and a vibrant atmosphere for fans. The initiative leverages BrewDog's physical locations to create shared, high-energy viewing experiences, aiming to drive traffic and reinforce brand engagement within Tilray's broader beverage strategy.

S&P 500 futures are rising in premarket trading, with Western Digital Corp. (WDC) up 8.7% and Agilent Technologies Inc. (A) up 7.5%. These gains come as the U.S. stock markets prepare to open in two hours.

TransUnion has appointed Clayton Ruebensaal as its new Chief Marketing and Communications Officer to strengthen its market positioning. Ruebensaal, who previously held senior marketing roles at Comcast, American Express, and The Ritz-Carlton, will oversee Corporate Marketing, Product Marketing, and Corporate Affairs and Communications. This move comes as TransUnion's stock is trading near its 52-week low, and the company seeks to enhance its brand communication and product impact.

Moderna has announced organizational changes to prepare for the launch of up to three new vaccines in 2027 and 2028, focusing on infectious diseases, intismeran, and rare diseases. Dr. Stephen Hoge, President, will take on expanded operational oversight, and Ester Banque has been appointed Chief Commercial Officer to build global commercial capabilities for upcoming product launches. The company also anticipates significant clinical milestones in 2026 for its intismeran autogene and propionic acidemia programs.

Moderna announced organizational changes aimed at supporting its ambitious long-range plan and preparing for multiple product launches in 2027 and 2028. Dr. Stephen Hoge, President of Moderna, will expand his role to oversee operational and cross-functional leadership across the company's three franchises. Additionally, Ester Banque has been appointed as Chief Commercial Officer to build out the global commercial organization and lead product launches.

Surf Air Mobility Inc. (NYSE: SRFM) highlighted its participation in Palantir Technologies' AIPCon 10, where it showcased its SurfOS™ software, enhanced with Palantir's Artificial Intelligence Platform (AIP), featuring BrokerOS. Co-Founder Liam Fayed also appeared in Palantir's "In the Field" video series, detailing Surf Air Mobility's vision and software use. The company emphasizes its role in modernizing air operations and adopting next-generation aircraft through its AI-enabled SurfOS platform.

University of Texas Texas AM Investment Management Co. has invested $6.04 million in Altria Group, acquiring 104,759 shares in the fourth quarter, making it their 16th largest holding. Altria Group, Inc. (NYSE:MO) reported better-than-expected first-quarter earnings and increased its quarterly dividend to $1.06 per share, offering an annualized yield of 6.1%. Analysts currently hold a consensus "Hold" rating on the stock with an average price target of $70.44.

A Discounted Cash Flow (DCF) analysis for PNC Financial Services Group Inc (PNC) indicates a mixed valuation. An earnings-based DCF model values PNC at $247.27, suggesting it is fairly valued with a 6.8% margin of safety, while a Free Cash Flow (FCF) based DCF model suggests slight overvaluation at $223.58. GuruFocus's proprietary GF Value™ further indicates the stock is 13.9% overvalued at $202.37, leading to a cautious stance for investors.

Moderna has announced organizational changes, including an expanded role for President Stephen Hoge and the appointment of Ester Banque as Chief Commercial Officer. These changes are intended to strengthen the company's operating model as it prepares for potential launches of up to three new products in 2027 and 2028, including combination and seasonal flu vaccines, and norovirus vaccines. Dr. Hoge will now oversee Research & Development, Manufacturing, and Commercial operations across Moderna's three franchises, while Banque brings extensive experience from previous roles at Zoetis, Bristol Myers Squibb, and Novartis.